Summit Investment Advisors Inc. Sells 155 Shares of Agilent Technologies, Inc. (NYSE:A)

Summit Investment Advisors Inc. lowered its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 5.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,800 shares of the medical research company’s stock after selling 155 shares during the period. Summit Investment Advisors Inc.’s holdings in Agilent Technologies were worth $376,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in A. CKW Financial Group grew its stake in Agilent Technologies by 114.9% in the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 100 shares during the period. Global X Japan Co. Ltd. increased its stake in Agilent Technologies by 161.1% during the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 116 shares in the last quarter. Redwood Park Advisors LLC bought a new position in shares of Agilent Technologies in the fourth quarter valued at $27,000. Lee Danner & Bass Inc. bought a new stake in shares of Agilent Technologies during the fourth quarter worth about $29,000. Finally, Hanson & Doremus Investment Management lifted its position in Agilent Technologies by 66.5% in the 4th quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 105 shares in the last quarter. 87.42% of the stock is currently owned by institutional investors and hedge funds.

Agilent Technologies Price Performance

Shares of NYSE A opened at $102.38 on Friday. The stock has a fifty day moving average of $119.55 and a 200-day moving average of $132.40. The stock has a market cap of $29.19 billion, a PE ratio of 23.54, a price-to-earnings-growth ratio of 2.89 and a beta of 1.19. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $155.35.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The company had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. Equities research analysts anticipate that Agilent Technologies, Inc. will post 5.54 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be paid a $0.248 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.97%. Agilent Technologies’s dividend payout ratio is currently 22.76%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. TD Cowen raised their target price on Agilent Technologies to $135.00 and gave the company a “buy” rating in a report on Thursday, April 10th. Robert W. Baird lowered their target price on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. Wells Fargo & Company cut their price target on shares of Agilent Technologies from $155.00 to $135.00 and set an “overweight” rating on the stock in a report on Thursday. Barclays cut their target price on Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. Finally, StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $144.58.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of Agilent Technologies stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the sale, the chief executive officer now owns 39,652 shares of the company’s stock, valued at $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the transaction, the vice president now owns 21,786 shares in the company, valued at $2,657,456.28. This trade represents a 8.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,638 shares of company stock valued at $731,229. 0.26% of the stock is owned by corporate insiders.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.